SCHEMBL3467030

SCHEMBL3467030

Cc1nc(N)c(C(N)=O)nc1-c1noc(C2CCCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 3/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PPARA Q07869 1/20 0.36
MAPK1 P28482 1/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3467024 0.66 NPC1 (0.44) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL3460867 0.65 ACVR2A (0.44) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL30793018 0.65 PDPK1 (0.50) KDM4EHSD17B10CYP1A2CYP2D6CYP2C19
SCHEMBL26039163 0.65 PDPK1 (0.50) KDM4EHSD17B10CYP1A2CYP2D6CYP2C19
SCHEMBL11621519 0.65 BMP1 (0.43) NPC1RAB9ACYP2C19ALDH1A1SMN1; SMN2
SCHEMBL3460348 0.65 ACVR2A (0.46) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL14363662 0.62 NPC1 (0.53) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL3828944 0.62 ADCY1 (0.37) NPC1RAB9AKDM4ECYP2C19ALDH1A1
SCHEMBL17328704 0.62 PPARA (0.40) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL12467093 0.61 SMYD3 (0.56) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 US disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 NPC1 4361/4885RAB9A 2909/4885CASP3 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.